{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-25-000006","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.391684+00:00","generated_at":"2026-05-28T05:58:31.703009+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)","bullets":["Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.","Full-year gross margin expected above 75.5%; cash and investments $39.5M, up $2.5M from 2023.","Growth driven by commercial execution in Extremities, OMF-Head & Neck, and Resensation adoption.","Investor Day scheduled for March 4, 2025 to discuss strategic priorities."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-25-000006","json":"https://secwatch.observer/filing/0000805928-25-000006.json","markdown":"https://secwatch.observer/filing/0000805928-25-000006.md","text":"https://secwatch.observer/filing/0000805928-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000006/0000805928-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000006/axgn-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:58:31.703009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}